10/28/20 8:31 AMNYSE : ABBVAbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ(TM) (upadacitinib) and HUMIRA(R) (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology'sRHEA-AIneutral
10/28/20 8:00 AMNYSE : ABBVAllergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of PresbyopiaAllergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment ofRHEA-AIneutral
10/19/20 10:06 AMNYSE : ABBVAbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ(TM) (upadacitinib) in Atopic DermatitisAbbVie (NYSE: ABBV) today announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for RINVOQ(TM) (upadacitinib) for the treatment of adults (15 mg and 30 mg, onceRHEA-AIneutral
10/19/20 8:56 AMNYSE : ABBVAbbVie Announces Commencement of Registered Exchange Offers("AbbVie") announced today the commencement of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior unsecured notes previously issued on November 21, 2019RHEA-AIneutral
10/16/20 7:34 PMNYSE : ABBVVENCLEXTA(R) (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA(R) (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment ofRHEA-AIpositive
10/09/20 9:00 AMNYSE : ABBVAllergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual MeetingToday, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.The scheduled times (noted in localRHEA-AIneutral
10/07/20 8:00 AMNYSE : ABBVAllergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler BusinessToday Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into an agreement with Luminera, a privately held, aesthetics company based in Israel with a portfolio and pipeline of dermal filler products.Under the terms of theRHEA-AIvery positive
10/06/20 8:00 AMNYSE : ABBVAbbVie to Host Third-Quarter 2020 Earnings Conference CallAbbVie (NYSE: ABBV) will announce its third-quarter 2020 financial results on Friday, October 30, 2020, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible throughRHEA-AIneutral
10/02/20 8:30 AMNYSE : ABBVAbbVie to Present New Data From 15 Abstracts at the 2020 Virtual Migraine Trust International SymposiumAbbVie (NYSE: ABBV) today announced it will present results from several clinical trials, including new data from the Phase 3 ADVANCE trial, evaluating the efficacy and safety of the investigational medicine atogepant, an orally administeredRHEA-AIneutral
09/28/20 8:00 AMNYSE : ABBVAbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord InjuryAbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational treatment for patients following spinal cord injury.ElezanumabRHEA-AIneutral
